Lidon, L. | Search bioRxiv

bioRxiv2026

cis-gamma-Amino-L-proline peptides as chemical probes of amyloidogenic processing in neurons and APP/PS1 mice

Alzheimers disease (AD) is characterized by the accumulation of amyloid-{beta} (A{beta}) peptides, which are a key factor in its pathogenesis. In this study, we present the design and evaluation of {gamma}-amino-L-proline peptides as metabolically stable, cell-penetrating molecules that can modulate amyloidogenic processing. We screened a library of {gamma}-peptides in primary neuronal cultures to determine their effects on endogenous A{beta}1-42 production, cytotoxicity, and {beta}-secretase (BACE1) activity. Comparative analysis of structurally related analogues enabled the identification of molecular features associated with A{beta}-lowering activity, establishing a qualitative structure-activity relationship. Peptide 33 (P33) emerged as a lead candidate, selectively reducing BACE1 activity without significantly inhibiting the homologous enzyme, BACE2. In vitro blood-brain barrier (BBB) assays revealed that P33 exhibits favorable transendothelial permeability. Intraperitoneal administration of P33 in APP/PS1 mice decreased A{beta} levels, reduced amyloid plaque burden, and improved performance in a behavioral recognition task without inducing cytotoxicity or systemic toxicity. These results define cis-{gamma}-amino-L-proline peptides as a bioorganically distinct and modular scaffold for the development of intracellular modulators of A{beta} production. HighlightsO_LI{gamma}LJAminoLJLLJproline peptides as metabolically stable modulators of A{beta} production. C_LIO_LIP33 showed BBB permeability and BACE1 inhibition in primary cortical neurons. C_LIO_LIIn APP/PS1 mice, P33 lowers amyloid burden and improves cognition. C_LIO_LIP33 shows good biocompatibility, supporting its therapeutic potential in AD C_LI

neuroscience↗

bioRxiv2024

Involvement of the cellular prion protein in seeding and spreading of sarkosyl-derived fractions of Alzheimer's disease in Prnp mutant mice and in the P301S transgenic tauopathy mice model

The natural cellular prion protein is known to play several roles during development and adult brain. Far from its pathological roles in prionopathies, the non-pathogenic cellular prion protein has been described as a receptor for several amyloid in oligomeric and prefibrillar forms. For some amyloids, specific domains of the protein play a crucial role in modulating amyloids cellular uptake and seeding properties. In most studies, the functions and the role of putative amyloid receptors have been analyzed by using brain extracts derived from human neurodegenerative patients. Another strategy has been to modify the genetic dosage of the natural prion protein in genetic models of different diseases. In this study, we take advantage of both approaches to examine whether this protein plays a role in the seeding and spreading of pathogenic tau. Our results point to a role of the natural prion protein in the emergence of pathogenic tau in a mouse model overexpressing the mutation P301S of the human tau gene. In contrast, its role is minor when sarkosyl-derived brain samples of Alzheimers disease are used. In fact, our results indicate that the use of this type of sample is not adequate to determine the role of a putative receptor in tau seeding and spreading.

neuroscience↗